United Kingdom
Achilles Therapeutics plc, founded in 2016 and headquartered in the United Kingdom, operates at the intersection of Biotechnology, Health Care, and Health and Wellness. The company is pioneering next-generation, personalized therapies that leverage the immune system to eradicate cancer cells.
With the slogan "Personalised T cell therapies targeting clonal neoantigens", Achilles Therapeutics focuses on developing therapies that target truncal tumor neo-antigens. These neo-antigens are unique immune system markers found only on cancer cells, offering the potential to attack tumors without harming healthy tissues. This groundbreaking approach is anchored in the expertise of its four scientific founders specializing in cancer evolution, bioinformatics, and immunotherapy.
The company's most recent funding, a €4.00M grant investment received on 21 July 2022, indicates continued support for its revolutionary approach in cancer treatment.
